CLAIMS

1. The use of nitrogeneous polycyclic derivatives for preparing drugs for treating neurodegenerative diseases, said derivatives having formula (I)



wherein

- Rn is anyone of R1, R2, R3 and R4, which are identical or different and represent H or represent one or several radicals and are selected in the group comprising –OH, an alkyl radical, –O-alkyl group, $-NH_2$,-NH-alkyl, -N (R5, R6), the alkyl being in said radical or groups a C1-C6 alkyl, or an halogen selected between the group consisting of F, Cl, Br,

- Y

- forms a phenyl group with both pyridines, optionally ortho-substituted by a substituent R5, or ortho-disubstituted by R5 and R6, said substituents being identical or different, and selected in the group comprising an alkyl radical, -O-alkyl group, $-NH_2$,-NH-alkyl, -N (R5, R6), the alkyl being in said radical or groups a C1-C6 alkyl, or an halogen selected between the group consisting of F, Cl, Br, or

- represents a group - $(CH_2)_{m1}$-W - $(CH_2)_{m1}$-, with m1 and m2 being 0, 1 or 2, and W being a group $-CH_2-$, -CH (R7), O,

or N (R8, R9), R7, R8 and R9, identical or different, being a C1-C3 alkyl radical, or H,

- Z is a linking arm of formula - A- $(CH_2)_n$-U- $(CH_2)_n$-A-,
  - A being O or NH, and
  - U being selected in the group comprising - $(CH_2)_{n1}$-, - N (R1,R2), -COOH, -OH,

with n being a number from 2 to 6, preferably from 2 to 4, and n1 being 0 or 1,

and the complexes thereof with transition metals, particularly with copper, zinc or iron.

2. The use according to claim 1, wherein said derivatives include 2 cyclic moieties.

3. The use according to claim 1, wherein said derivatives include 3 cyclic moieties.

4. The use according to claim 1, wherein said derivatives include 4 cyclic moieties.

5. The use according to anyone of claims 1 to 4, wherein, in said derivatives, the cyclic moieties consist of Phen moieties.

6. The use according to claim 5, wherein said derivatives are polycyclic Phen having formula (II)



7. The use according to anyone of claims 1 to 6, for treating degenerative diseases comprising Alzheimer, Parkinson, Huntington diseases.

8. The use according to anyone of the preceding claims, wherein the drugs comprise an effective amount of at least one derivative as defined in anyone of claims 1 to 6, associated with a pharmaceutical inert vehicle.

9. The use according to claim 8, wherein the drug is administered by the oral, intramuscular and intravenous route.

10. The use according to claim 9, wherein, for oral administration, the drugs are presented in the form of tablets, pills, capsules or drops, patch, spray.

11. The use according to claim 9, wherein for administration by injection, the drugs are under the form of solution for injection by the intravenous, subcutaneous or intramuscular route produced from sterile or sterilisable solution, or suspension or emulsion.

12. A method for preparing the derivatives of anyone of claims 1 to 6, comprising reacting

- a dihydroxy bipyridine derivative of formula (III)



with

- a ditosyl derivative of formula (IV)



wherein Rn, Y and Z are as defined in claim 1.

13. The method of claim 12, wherein the reaction is carried out with high dilution conditions.

14. The method of claim 12 or 13, comprising the use of cesium carbonate.

15. Application of the derivatives defined in anyone of claims 1 to 6 as chelating agents of transition metals.